Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 4
Submit an article Journal homepage
30
Views
9
CrossRef citations to date
0
Altmetric
Miscellaneous

β-Amyloid peptide as a target for treatment of Alzheimer’s disease

Santiago Conde Instituto de Química Médica (C.S.I.C.), Juan de la Cierva 3, 28006 Madrid, Spain, Tel: +34 91 5622900; Fax: +34 915644853;, E-mail: [email protected]
Pages 503-512 | Published online: 25 Feb 2005

Bibliography

  • ABRAHAM CR: Amyloid 13 peptide: a century of discoveries. Int. j Chh. Invest. (2000) 7:7–9.
  • GLENNER GG, WONG CW: Alzheimer's disease and Down's syndrome: sharing a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. (1984) 122:1131–1135.
  • SELKOE DJ: Amyloid I3-protein and the genetics of Alzheimer's disease. j Biol. Chem. (1996) 271:18295–18298.
  • ••Comprehensive description of the amyloidhypothesis and data supporting it.
  • THORSETT ED, LATIMER LH: Therapeutic approaches to Alzheimer's disease. Curr. Opin. Chem. Biol. (2000) 4:377–382.
  • ••Potential treatments for AD.
  • JHEE S, SHIOVITZ T, CRAWFORD AW, CUTLER NR: I3-Amyloid therapies in Alzheimer's disease. Expert Opin. Investig. Drugs (2001) 10(4):593–605.
  • ••Basic general survey of the AD treatmentapproaches related to amyloid peptide.
  • SAIDO TC: Degradation of amyloid-I3 peptide: a key to Alzheimer pathogenesis, prevention and therapy. Neurosci. News (2000) 3:52–62.
  • SEO J, KIM S, KIM H et al.: Effects of nicotine on APP secretion and A13- or CT(105)-induced toxicity. Biol. Psychiatry (2001) 49:240–247.
  • SELKOE DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 399(6738 Suppl.):A23–31.
  • LAHIRI DK, GE YW, FARLOW MR: Effect of a memory-enhancing drug, AIT-082, on the level of synaptophysin. Ann. N Y Acad. Li. (2000) 903:387–393.
  • OPAZO C, RUIZ FH, INESTROSA NC: Amyloid-13-peptide reduces copper (II) to copper (I) independent of its aggregation state. Biol. Res. (2000) 33:125–131.
  • HOWLETT DR, SIMMONS DL, DINGWALL C, CHRISTIE G: In search of an enzyme: the I3-secretase of Alzheimer's disease is an aspartic proteinase. Trends Neurosci. (2000) 23:565–570.
  • FARZAN M, SCHNITZLER CE, VASILIEVA N, LEUNG D, CHOE H: BACE2, a I3-secretase homolog, cleaves at the 13 site and within the amyloid-I3 region of the amyloid-I3 precursor protein. Proc. Nati Acad. Sci. USA (2000) 97:9712–9717.
  • GHOSH AK, SHIN D, DOWNS D et al.: Design of potent inhibitors for human brain memapsin 2 (I3-secretase). j Am. Chem. Soc. (2000) 122:3522–3523.
  • HONG L, KOELSCH G, LIN X etal. Structure of the protease domain of memapsin 2 (I3-secretase) complexed with inhibitor. Science (2000) 290:150–153.
  • GHOSH AK, BILCER G, HARWOOD C et al.: Structure-based design: potent inhibitors for human brain memapsin 2 (p-secretase). J Med. Chem. (2001) 44:2865–2868.
  • OLSON RE, THOMPSON LA: Secretase inhibitors as therapeutics for Alzheimer's disease. In: Ann. Reports Med. Chem. (2000) 35(Chap. 4):31–40.
  • •General survey of secretases inhibitors as potential treatment for AD.
  • DE STROOPER B, SAFTIG P, CRAESSAERTS K et al.: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 391:387–390.
  • WOLFE MS, XIA W, OSTASZEWSKI BL, DIEHL TS, KIMBERLY WT, SELKOE DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and y-secretase activity. Nature (1999) 398:513–517.
  • CITRON M, WESTAWAY D, XIA W et al.: Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid I3-protein in both transfected cells and transgenic mice. Nat. Med. (1997) 3:67–72
  • YU G, NISHIMURA M, ARAWAKA S et al.: Nicastrin modulates presenilin-mediated notch/g1p-1 signal transduction and I3APP processing. Nature (2000) 407:48–54.
  • SCHENK D: A partner for presenilin. Nature (2000) 407:34–35.
  • ••Hypothesis of the cleavage of APP byy-secretase.
  • HADLAND BK, MANLEY NR, SU D et al.: y-secretase inhibitors repress thymocyte development. Proc. Nati Acad. Li. USA (2001) 98:7487–7491.
  • •Potential side effects of ysecretase inhibition.
  • KOZLOWSKI MR, SPANOYANNIS A, MANLY SP, FIDEL SA, NEVE RL: The neurotoxic carboxy-terminal fragment of the Alzheimer amyloid precursor binds specifically to a neuronal cell surface molecule: pH dependence of the neurotoxicity and the binding. j Neurosci. (1992) 12:1679–1687.
  • HIGAKI JN, CHAKRAVARTY S, BRYANT CM et al.: A combinatorial approach to the identification of dipeptide aldehyde inhibitors of 13-amyloid production. j Med. Chem. (1999) 42:3889–3898.
  • ••Application of combinatorial techniques tomedicinal chemistry.
  • WOLFE MS, CITRON M DIEHL TS et al.: A substrate-based difluoroketone selectively inhibits Alzheimer's y-secretase activity. I Med. Chem. (1998) 41:6–9.
  • SHEARMAN MS, BEHER D, CLARKE EE et al.: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid I3-protein precursor y-secretase activity. Biochemistry (2000) 39:8698–8704.
  • •Interactions enzyme/inhibitor.
  • DOVEY HF, JOHN V, ANDERSON JP et al.: Functional y-secretase inhibitors reduce 13-amyloid peptide levels in brain. Neurochem. (2001) 76:173–181.
  • •First demonstrated reduction of brain Ap in vivo.
  • LANSBURY PT: Evolution of amyloid: what normal protein folding may tell us about flbrillogenesis and disease. Proc. Nati Acad. Sci. USA (1999) 96:3342–3344
  • ALLAIN H, BENTUE-FERRER D, ZEKRI O, SCHUCK S, LEBRETON S, REYMANN JM: Experimental and clinical methods in the development of anti-Alzheimer drugs. Fundam. Gun. Pharmacol. (1998) 12:13–29.
  • GEULA C, WU CK, SAROFF D, LORENZO A, YUAN M, YANKNER BA: Aging renders the brain vulnerable to amyloid I3-protein neurotoxicity. Nat. Med. (1998) 4:827–831.
  • HARPER JD, LANSBURY PT: Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Ann. Rev. Biochem. (1997) 66:385–407.
  • TALAGA P: P-Amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality? Mini Rev. Med. Chem. (2001) 1:175–186.
  • ••Updated review on amyloid aggregation.
  • LORENZO A, YANKNER BA: P-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc. Nati Acad. Sci. USA (1994) 91:12243–12247.
  • LEVINE H: Thioflavine T interaction with synthetic Alzheimer's disease P-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. (1993) 2:404–410.
  • TVVYMAN LJ, ALLSOP D: A short synthesis of the P-amyloid (AP) aggregation inhibitor 3-p-toluoyl 2 [4' (3 diethyl-aminopropoxy)-phenyll-benzofuran. Tetrahedron Lett. (1999) 40:9383–9384.
  • SOTO C: Protein misfolding and disease: protein refolding and therapy. FEBS Lett. (2001) 498:204–207.
  • SOTO C, SABORIO GP, PERMANNE B: Inhibiting the conversion of soluble amyloid-P peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy. Acta. Neurol. Scary/. Suppl. (2000) 176:90–95.
  • FINDEIS MA: Approaches to discovery and characterization of inhibitors of amyloid 3-peptide polymerization. Biochim. Biophys. Acta (2000) 1502:76–84.
  • FINDEIS MA, MUSSO GM, ARICO-MUENDEL CC et al.: Modified-peptide inhibitors of amyloid 3-peptide polymerization. Biochemistry (1999) 38:6791–800.
  • GHANTA J, SHEN CL, KIESSLING LL,MURPHY RM: A strategy for designing inhibitors of P-amyloid toxicity. _J. Biol. Chem. (1996) 271:29525–29528.
  • PALLITTO MM, GHANTA J, HEINZELMAN P, KIESSLING LL, MURPHY RM: Recognition sequence design for peptidyl modulators of 13-amyloid aggregation and toxicity. Biochemistry (1999) 38:3570–3578.
  • SOLOMON B, KOPPEL R, FRANKEL, D, HANAN-AHARON E: Disaggregation of Alzheimer P-amyloid by site-directed mAb. Proc. Natl. Acad. Li. USA (1997) 94:4109–4112.
  • GAMES D, ADAMS D, ALESSANDRINI R et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F 13-amyloid precursor protein. Nature (1995) 373:523–527.
  • •Transgenic mice (ADAPP) developed by Athena Neurosciences.
  • HSIAO K, CHAPMAN P, NILSEN S et al.: Correlative memory deficits, AP elevation and amyloid plaques in transgenic mice. Science (1996) 274:99–102.
  • •Transgenic mice (Hsiao Tg 2576) developed by researchers at the University of Minnesota.
  • STURCHLER-PIERRAT C, ABRAMOWSKI D, DUKE M etal.: Two amyloid precursor protein transgenic mouse models with Alzheimer's disease-like pathology. Proc. Nati Acad. Li. USA (1997) 94:13287–13292.
  • •Transgenic mice (APP23) developed by Novartis Pharma.
  • CHISHTI MA, YANG DS, JANUS C et al.: Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. _J. Biol. Chem. (2001) 276:21562–21570.
  • ••Double mutant transgenic mice(TgCRND8) developed by researchers at the University of Toronto. A potent tool for biological tests.
  • SOLOMON B, FRENKEL D: Vaccination for the prevention and treatment of Alzheimer's disease. Drugs Today (2000) 36:655–663.
  • ••Detailed description of the immunisationprocess.
  • SCHENK DB, BARBOUR R, DUNN W et al.: Immunization with amyloid-P attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173–177.
  • ••Basic work on the immune approach. Thefirst report of a treatment that reduces AD progression in a transgenic animal model.
  • SCHENK DB, SEUBERT P, LIEBERBURG I, WALLACE J: Peptide immunization. A possible new treatment for Alzheimer's disease. Arch. Neurol. (2000) 57:934–936.
  • BARD F, CANNON C, BARBOUR R etal.: Peripherally administered antibodies against amyloid 3-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. (2000) 6:916–919.
  • ••Assertion that antibodies against AP couldcross the blood-brain barrier to act directly in the CNS.
  • DEMATTOS RB, BALES KR, CUMMINS DJ, DODART JC, PAUL SM, HOLTZMAN DM: Peripheral anti-A13 antibody alters CNS and plasma AP clearance and decreases brain AP burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA (2001) 98:8850–8855.
  • ••Reduction of AP deposition in brain maybe due to a change in the AP equilibrium between the CNS and plasma, by clearing AP from plasma.
  • JANUS C, PEARSON J, MCLAURIN JA etal.: AP peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979–982.
  • •Confirmation of the efficacy of immunisation with AP in a second animal model.
  • SIGURDSSON EM, SCHOLTZOVA H, MEHTA PD, FRANGIONE B, WISNIEWSKI T: Immunisation with nontoxidnonflbrillar amyloid-3 homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J Pathol. (2001) 159:439–447.
  • ••A new and possibly safer form of ADvaccine.
  • KLEIN WL, KRAFFT GA, FINCH CE: Targeting small AP oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. (2001) 24:219–224.
  • •This work explains the idea that fibrils and AP deposits are not the only and perhaps even the most relevant toxic form of AP: protofibrils and small oligomers may also play an important role in the neurotoxic process.

Websites

  • BioSpace News http://www.biospace.com/ news_story.cfm?StoryID8062715&full1

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.